A Drug- Drug Interaction Study of JI-101 and Everolimus in Patients With Advanced Solid Tumors Refractory to Therapy With an Expansion Pharmacodynamic Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Trial Profile

A Drug- Drug Interaction Study of JI-101 and Everolimus in Patients With Advanced Solid Tumors Refractory to Therapy With an Expansion Pharmacodynamic Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Sep 2015

At a glance

  • Drugs JI 101 (Primary) ; Everolimus
  • Indications Colorectal cancer; Head and neck cancer; Ovarian cancer; Solid tumours
  • Focus Pharmacogenomic; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 14 Sep 2015 Results (single agent in an ovarian cancer expansion cohort) published in the Investigational New Drugs.
    • 14 Aug 2012 Actual end date (August 2012) added as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top